Rafferty Asset Management LLC Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Rafferty Asset Management LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLXFree Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,931 shares of the medical equipment provider’s stock after selling 633 shares during the period. Rafferty Asset Management LLC’s holdings in Hologic were worth $1,781,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of HOLX. Deseret Mutual Benefit Administrators increased its position in Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares in the last quarter. Arizona State Retirement System boosted its position in Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after purchasing an additional 172 shares during the period. Lincoln National Corp raised its position in Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 178 shares during the period. Allworth Financial LP lifted its stake in shares of Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares in the last quarter. Finally, Great Lakes Retirement Inc. grew its stake in shares of Hologic by 1.6% in the fourth quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock valued at $847,000 after buying an additional 186 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

HOLX opened at $73.97 on Tuesday. The firm has a market capitalization of $17.26 billion, a PE ratio of 37.74, a PEG ratio of 2.48 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $82.45. The business’s 50-day simple moving average is $75.60 and its 200 day simple moving average is $74.09. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLXGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 EPS. As a group, sell-side analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HOLX. Argus raised their target price on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $85.60.

Read Our Latest Report on Hologic

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Recommended Stories

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.